DOI:
10.1055/s-00000133
Gastroenterologie up2date
LinksClose Window
References
Demetri GD, Reichardt P, Kang YK. et al.
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Lancet 2013;
381: 295-302
We do not assume any responsibility for the contents of the web pages of other providers.